New target-seeking molecule offers hope of better cancer treatment
A new target-seeking affibody molecule can be used to visualize cancer tumors and to treat them. This has been shown in a dissertation by Ann-Charlott Steffen to be publicly defended at Uppsala University on April 22.
The gamma camera image shows the distribution of radioactivity in a mouse given target-seeking affibody molecules marked with radioactivity. The uptake can be seen in the thyroid gland, the kidneys, and the tumor.
Every third Swede is estimated to receive a cancer diagnosis sometime in their lives, and nearly one Swede in four dies as a result of the disease. The need for improved detection and treatment of the disease is great.
Existing treatments include surgery, chemotherapy, and radiation. Surgery is most effective for large, well-defined tumors, but if the disease has spread, chemotherapy and/or radiation are needed. These forms of treatment affect all dividing cells, leading to toxic effects on healthy tissue. This toxicity limits the size of the dose that can be given, thereby also limiting the probability that the disease will be cured. By seeking out tumor cells and selectively delivering cytostatics or radiation to the cancer cells, the dose affecting healthy tissue can be reduced and the dose to the tumor can be increased. This improves the chances of curing the disease.
Ann-Charlott Steffen and her associates have developed an affibody molecule that binds to the protein HER-2, which primarily occurs in cancer cells from patients with aggressive forms of breast cancer. The scientists have attached radioactivity to the affibody molecules, so that they can visualize tumors and metastases and also treat tumors with the local dose of radiation provided by this radioactivity.
Ann-Charlott Steffen shows that the HER-2-binding affibody molecules attach to cancer cells with the HER-2 target on their surface, both in cell cultures and in mouse tumors. The research team has also found that the radioactivity in mouse tumors can be used to make these tumors visible in a gamma camera (see picture). Moreover, the results show that the radioactivity delivered by the affibody molecules can be used to kill tumor cells in cell cultures.
Affibody molecules are tiny, which enables them to enter tumors and be rapidly distributed in the body, unlike antibodies, which are normally used in target-seeking therapy and visualization. Whats more, affibody molecules are relatively easy to develop for virtually any target and can therefore in all probability be used for visualizing and treating many different forms of cancer.
“I hope these findings will lead to new possibilities of visualizing and treating distributed tumor diseases so that more cancer patients will be able to survive,” says Ann-Charlott Steffen.
Linda Nohrstedt | alfa
The most recent press releases about innovation >>>
Die letzten 5 Focus-News des innovations-reports im Überblick:
Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.
As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...
Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.
Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...
For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.
While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...
An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.
The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...
A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.
Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...